Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as First Line Therapy in Chemotherapy Naive Patients With Extensive Disease (ED) Stage Small Cell Lung Cancer (SCLC)

NCT00299390 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00299390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00299390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as First Line Therapy in Chemotherapy Naive Patients With Extensive Disease (ED) Stage Small Cell Lung Cancer (SCLC)
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2006
Completion date
April 30, 2007
Enrollment
10 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma